Stephens & Co. Confirms Overweight Rating for Pennant Group (PNTG)
Analyst Recommendation: Stephens & Co. has reiterated an Overweight recommendation for Pennant Group (NasdaqGS:PNTG), with an average one-year price target of $34.27/share, indicating a potential upside of 36.76% from its current price of $25.06/share.
Fund Sentiment: There are 386 funds reporting positions in Pennant Group, with a slight increase in ownership and a bullish put/call ratio of 0.19, suggesting positive market sentiment.
Shareholder Activity: Notable changes in shareholder positions include Van Berkom & Associates and 8 Knots Management increasing their allocations, while Ophir Asset Management significantly raised its stake by 311.80%.
Revenue Projections: The projected annual revenue for Pennant Group is $550 million, reflecting a decrease of 31.13%, with a projected non-GAAP EPS of 0.98.
Trade with 70% Backtested Accuracy
Analyst Views on PNTG
About PNTG
About the author
The Pennant Group (PNTG) Sees Stock Increase: Here's the Reason Why
Stock Performance: Shares of The Pennant Group rose 4.5% following a positive consensus 'Buy' rating from analysts, with a potential upside of over 22% based on an average price target of $34.33.
Market Sentiment: The stock's rise was influenced by comments from New York Federal Reserve President John Williams, which increased expectations for an interest rate cut, boosting market confidence amid high valuations in AI stocks.
Wells Fargo Raises Rating on Pennant Group (PNTG)
Wells Fargo Upgrade: On November 18, 2025, Wells Fargo upgraded Pennant Group's outlook from Equal-Weight to Overweight, with an average one-year price target of $34.00/share, indicating a potential upside of 33.86% from its closing price of $25.40/share.
Institutional Ownership Trends: There are 401 funds reporting positions in Pennant Group, reflecting a 7.22% increase in ownership over the last quarter, with total shares owned by institutions rising by 2.79% to 35,470K shares.
Fund Sentiment: The put/call ratio for Pennant Group is 0.92, suggesting a bullish sentiment among investors, while several firms have adjusted their portfolio allocations, with some increasing and others decreasing their holdings.
Projected Financials: The projected annual revenue for Pennant Group is estimated at $550 million, representing a decrease of 35.06%, with a projected non-GAAP EPS of 0.98.
The Pennant Group, Inc. (PNTG) Exceeds Q3 Earnings and Revenue Projections
Earnings Performance: The Pennant Group, Inc. reported quarterly earnings of $0.30 per share, exceeding the Zacks Consensus Estimate of $0.29, and showing an increase from $0.26 per share a year ago. The company has surpassed consensus EPS estimates three out of the last four quarters.
Revenue Growth: The company generated revenues of $229.04 million for the quarter, surpassing the Zacks Consensus Estimate by 2.71% and up from $180.69 million year-over-year. It has also topped revenue estimates in all four of the last quarters.
Stock Outlook: Despite the positive earnings report, The Pennant Group's shares have declined by 4.7% since the start of the year, underperforming the S&P 500's 15.1% gain. The stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Industry Context: The Medical - Outpatient and Home Healthcare industry, to which The Pennant Group belongs, is currently ranked in the top 18% of Zacks industries, suggesting a favorable outlook. Investors are advised to monitor earnings estimate revisions for future performance insights.
Preview of The Pennant Group (PNTG) Q3 Earnings Report: Key Insights to Anticipate
Earnings Announcement: The Pennant Group will announce its earnings results this Wednesday, having previously exceeded revenue expectations by 4.2% last quarter with revenues of $219.5 million, a 30.1% year-on-year increase.
Analyst Expectations: For the upcoming quarter, analysts expect revenue growth of 23% year-on-year to $222.3 million, with adjusted earnings projected at $0.29 per share, indicating a slowdown compared to last year's growth.
Market Performance: The Pennant Group has consistently beaten revenue estimates over the past two years, averaging a 4.8% beat, while its stock has seen a 3.7% decline over the past month, with an average analyst price target of $33.
Industry Context: Peers in the senior health sector, such as BrightSpring Health Services and Addus HomeCare, have reported strong revenue growth, suggesting a stable outlook for the industry as investors remain cautious ahead of earnings.
Pennant to Release Third Quarter 2025 Earnings and Host Conference Call
Third Quarter Financial Results Announcement: The Pennant Group, Inc. will release its third quarter 2025 financial results on November 5, 2025.
Live Webcast for Investors: A live webcast discussing the financial results will take place on November 6, 2025, at 10:00 a.m. Mountain Time.
Access to Financial Information: Investors can access the webcast and related financial information on the Pennant Group's Investor Relations website.
Company Overview: The Pennant Group operates independent subsidiaries providing home health, hospice, and senior living services across multiple states in the U.S.
Albemarle Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Friday
Analyst Ratings Overview: Top Wall Street analysts have recently changed their outlook on several companies, with a focus on upgrades, downgrades, and new coverage initiations.
The Pennant Group, Inc.: Jefferies analyst Brian Tanquilut initiated coverage with a Buy rating and a price target of $30, while shares closed at $24.48.
Alphatec Holdings, Inc.: JP Morgan analyst Allen Gong initiated coverage with an Overweight rating and a price target of $19, with shares closing at $15.89.
ImageneBio, Inc. and Albemarle Corporation: Leerink Partners initiated coverage on ImageneBio with an Outperform rating and a $30 price target, while Rothschild & Co initiated coverage on Albemarle with a Buy rating and a $135 price target.
The Pennant Group (PNTG) Sees Stock Increase: Here's the Reason Why
Stock Performance: Shares of The Pennant Group rose 4.5% following a positive consensus 'Buy' rating from analysts, with a potential upside of over 22% based on an average price target of $34.33.
Market Sentiment: The stock's rise was influenced by comments from New York Federal Reserve President John Williams, which increased expectations for an interest rate cut, boosting market confidence amid high valuations in AI stocks.
Wells Fargo Raises Rating on Pennant Group (PNTG)
Wells Fargo Upgrade: On November 18, 2025, Wells Fargo upgraded Pennant Group's outlook from Equal-Weight to Overweight, with an average one-year price target of $34.00/share, indicating a potential upside of 33.86% from its closing price of $25.40/share.
Institutional Ownership Trends: There are 401 funds reporting positions in Pennant Group, reflecting a 7.22% increase in ownership over the last quarter, with total shares owned by institutions rising by 2.79% to 35,470K shares.
Fund Sentiment: The put/call ratio for Pennant Group is 0.92, suggesting a bullish sentiment among investors, while several firms have adjusted their portfolio allocations, with some increasing and others decreasing their holdings.
Projected Financials: The projected annual revenue for Pennant Group is estimated at $550 million, representing a decrease of 35.06%, with a projected non-GAAP EPS of 0.98.
The Pennant Group, Inc. (PNTG) Exceeds Q3 Earnings and Revenue Projections
Earnings Performance: The Pennant Group, Inc. reported quarterly earnings of $0.30 per share, exceeding the Zacks Consensus Estimate of $0.29, and showing an increase from $0.26 per share a year ago. The company has surpassed consensus EPS estimates three out of the last four quarters.
Revenue Growth: The company generated revenues of $229.04 million for the quarter, surpassing the Zacks Consensus Estimate by 2.71% and up from $180.69 million year-over-year. It has also topped revenue estimates in all four of the last quarters.
Stock Outlook: Despite the positive earnings report, The Pennant Group's shares have declined by 4.7% since the start of the year, underperforming the S&P 500's 15.1% gain. The stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Industry Context: The Medical - Outpatient and Home Healthcare industry, to which The Pennant Group belongs, is currently ranked in the top 18% of Zacks industries, suggesting a favorable outlook. Investors are advised to monitor earnings estimate revisions for future performance insights.
Preview of The Pennant Group (PNTG) Q3 Earnings Report: Key Insights to Anticipate
Earnings Announcement: The Pennant Group will announce its earnings results this Wednesday, having previously exceeded revenue expectations by 4.2% last quarter with revenues of $219.5 million, a 30.1% year-on-year increase.
Analyst Expectations: For the upcoming quarter, analysts expect revenue growth of 23% year-on-year to $222.3 million, with adjusted earnings projected at $0.29 per share, indicating a slowdown compared to last year's growth.
Market Performance: The Pennant Group has consistently beaten revenue estimates over the past two years, averaging a 4.8% beat, while its stock has seen a 3.7% decline over the past month, with an average analyst price target of $33.
Industry Context: Peers in the senior health sector, such as BrightSpring Health Services and Addus HomeCare, have reported strong revenue growth, suggesting a stable outlook for the industry as investors remain cautious ahead of earnings.
Pennant to Release Third Quarter 2025 Earnings and Host Conference Call
Third Quarter Financial Results Announcement: The Pennant Group, Inc. will release its third quarter 2025 financial results on November 5, 2025.
Live Webcast for Investors: A live webcast discussing the financial results will take place on November 6, 2025, at 10:00 a.m. Mountain Time.
Access to Financial Information: Investors can access the webcast and related financial information on the Pennant Group's Investor Relations website.
Company Overview: The Pennant Group operates independent subsidiaries providing home health, hospice, and senior living services across multiple states in the U.S.
Albemarle Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Friday
Analyst Ratings Overview: Top Wall Street analysts have recently changed their outlook on several companies, with a focus on upgrades, downgrades, and new coverage initiations.
The Pennant Group, Inc.: Jefferies analyst Brian Tanquilut initiated coverage with a Buy rating and a price target of $30, while shares closed at $24.48.
Alphatec Holdings, Inc.: JP Morgan analyst Allen Gong initiated coverage with an Overweight rating and a price target of $19, with shares closing at $15.89.
ImageneBio, Inc. and Albemarle Corporation: Leerink Partners initiated coverage on ImageneBio with an Outperform rating and a $30 price target, while Rothschild & Co initiated coverage on Albemarle with a Buy rating and a $135 price target.
